Therefore, understanding these crosstalks between immune system, tumor progression and gut microbiota is of utmost importance to adapt immunomodulatory drugs, such as ICI and drugs targeting the Trp-Kyn-AhR axis. The gene discussed is AHR; the disease is neoplasm.